

**Table 2.** Phase 3 RCT designs on biologics for CRSwNP.

Biologic Agent	CRSwNP Clinical Trials	Primary Endpoints	Secondary Endpoints
Dupilumab	LIBERTY NP SINUS-24 (n = 143) LIBERTY NP SINUS-52 (n = 295)	Endoscopic nasal polyp score  Mean daily nasal congestion score	Lund-Kennedy score  Patient-reported total symptom score  SNOT-22  UPSIT smell test
Omalizumab	POLYP-1 (n = 72) POLYP-2 (n = 62)	Endoscopic nasal polyp score  Mean daily nasal congestion score	SNOT-22  UPSIT score  Total nasal symptom score  Individual nasal symptom
Mepolizumab	SYNAPSE (n = 206)	Endoscopic nasal polyp score  VAS nasal congestion score	Overall symptoms  VAS  SNOT-22  Probability of surgery  Systemic steroid use

VAS = visual analogic scale; SNOT-22 = 22-item Sino-Nasal Outcome Test; UPSIT = University of Pennsylvania Smell Identification Test.